This randomized controlled clinical trial will identify the additional benefit of bismuth or
metronidazole in proton pump inhibitor-amoxicillin-containing therapy for Helicobacter pylori
first-line treatment. The completion of this trial will expand new therapy for the treatment
of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use
of antibiotics.